\-\ Texto\\:\\ \ \(0\)\
\-\ leukocytosis\\.\ \(11\)\
\-\ \\â\\€\\¢\\ cxr\\:\\ \\ interstitial\\ pattern\\,\\ pulmonary\\ nodules\\,\\ and\\ faint\\ mass\\ on\\ the\\ right\\.\\ \\ \ \(0\)\
\-\ \\â\\€\\¢\\ ct\\:\\ \\ multiple\\ cavitary\\ and\\ noncavitary\\ nodules\\ and\\ masses\\.\ \(0\)\
\-\ caplan\\ syndrome\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ vasculitis\ \(1\)\
\-\ \\â\\€\\¢\\ septic\\ emboli\ \(0\)\
\-\ \\â\\€\\¢\\ infection\ \(8\)\
\-\ 55\\ y\\.o\\.\\ coal\\ miner\\ approximately\\ two\\ months\\ status\\ post\\ posterior\\ cervical\\ fusion\\ for\\ c2\\-c3\\ instability\\.\\ \\ routine\\ clinical\\ followup\\ shows\\ a\\ leukocytosis\\.\\ \\ the\\ patient\\ has\\ known\\ rheumatoid\\ arthritis\\ and\\ exposure\\ to\\ coal\\ dust\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ coal\\:\\ 0\\.21097068164692348\ \(0\)\
\-\ leukocytosis\\:\\ 0\\.13662780162278143\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.12210501441006918\ \(0\)\
\-\ noncavitary\\:\\ 0\\.11448725225930519\ \(0\)\
\-\ caplan\\:\\ 0\\.10021956019868038\ \(0\)\
\-\ miner\\:\\ 0\\.10021956019868038\ \(0\)\
\-\ dust\\:\\ 0\\.09648342938761828\ \(0\)\
\-\ nodules\\:\\ 0\\.0920134770234481\ \(0\)\
\-\ c2\\-c3\\:\\ 0\\.0776922737650686\ \(0\)\
\-\ faint\\:\\ 0\\.07031585769226419\ \(0\)\
\-\ cavitary\\:\\ 0\\.06907806314935089\ \(0\)\
\-\ emboli\\:\\ 0\\.060076151713507435\ \(0\)\
\-\ septic\\:\\ 0\\.05824396212571646\ \(0\)\
\-\ exposure\\:\\ 0\\.05774117625323996\ \(0\)\
\-\ instability\\:\\ 0\\.057099711898310396\ \(0\)\
\-\ vasculitis\\:\\ 0\\.05679048269449587\ \(0\)\
\-\ interstitial\\:\\ 0\\.05429596669788134\ \(0\)\
\-\ 55\\:\\ 0\\.05380116350005964\ \(0\)\
\-\ followup\\:\\ 0\\.052978181500935105\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.05242071338772687\ \(0\)\
\-\ fusion\\:\\ 0\\.049500936597675835\ \(0\)\
\-\ arthritis\\:\\ 0\\.047412109740817984\ \(0\)\
\-\ cxr\\:\\ 0\\.04683158793668932\ \(0\)\
\-\ routine\\:\\ 0\\.044499307716233734\ \(0\)\
\-\ pattern\\:\\ 0\\.04242132907884777\ \(0\)\
\-\ cervical\\:\\ 0\\.040325862423267904\ \(0\)\
\-\ status\\:\\ 0\\.03961464053482667\ \(0\)\
\-\ masses\\:\\ 0\\.03751418698696218\ \(0\)\
\-\ known\\:\\ 0\\.03511754655147818\ \(0\)\
\-\ post\\:\\ 0\\.0349459095204194\ \(0\)\
\-\ approximately\\:\\ 0\\.034335296448773804\ \(0\)\
\-\ clinical\\:\\ 0\\.03414688052033772\ \(0\)\
\-\ pulmonary\\:\\ 0\\.03242273130155927\ \(0\)\
\-\ infection\\:\\ 0\\.032259955507439056\ \(0\)\
\-\ y\\.o\\:\\ 0\\.032030901721905196\ \(0\)\
\-\ two\\:\\ 0\\.03178352256644163\ \(0\)\
\-\ syndrome\\:\\ 0\\.03173904645109924\ \(0\)\
\-\ shows\\:\\ 0\\.0305113467497257\ \(0\)\
\-\ months\\:\\ 0\\.03031092590506581\ \(0\)\
\-\ \\:\\:\\ 0\\.029357787428328962\ \(0\)\
\-\ metastatic\\:\\ 0\\.027936485761247926\ \(0\)\
\-\ posterior\\:\\ 0\\.025579721411720113\ \(0\)\
\-\ multiple\\:\\ 0\\.023374103941289207\ \(0\)\
\-\ has\\:\\ 0\\.020840259357068545\ \(0\)\
\-\ disease\\:\\ 0\\.018139448587216937\ \(0\)\
\-\ ct\\:\\ 0\\.015523424070026532\ \(0\)\
\-\ mass\\:\\ 0\\.015434558531786553\ \(0\)\
\-\ right\\:\\ 0\\.011709502715719697\ \(0\)\
\-\ patient\\:\\ 0\\.011124570531381663\ \(0\)\
\-\ for\\:\\ 0\\.009468936995359938\ \(0\)\
\-\ on\\:\\ 0\\.009401181978771794\ \(0\)\
\-\ and\\:\\ 0\\.009351117180894465\ \(0\)\
\-\ \\,\\:\\ 0\\.007031430273176296\ \(0\)\
\-\ to\\:\\ 0\\.005546339070688133\ \(0\)\
\-\ a\\:\\ 0\\.005150646776864952\ \(0\)\
\-\ the\\:\\ 0\\.0035908905117824886\ \(0\)\
\-\ \\.\\:\\ 0\\.003227230554304207\ \(0\)\
